Lupus Nephritis May Be As Straightforward As Lupus R&D Gets
Some drug makers are tackling lupus R&D by focusing on a specific subset of the disease, lupus nephritis, where diagnosis is more clear cut and the clinical endpoints are more straightforward.
You may also be interested in...
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Long-term data from the AURA-LV study in lupus nephritis show voclosporin is superior to standard of care, raising expectations for future Phase III success.
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.